Table 4

Incremental cost-effectiveness analyses (CEAs) of the two smoking cessation treatments, HIT and LIT, for 6-month continuous abstinence at 1 year (CEA short term), sustained abstinence at 5–8 years of follow-up (CEA long term), and sensitivity analyses for CEA long term. Societal perspective, in Euro 2018

Intervention costs	CEA* short	CEA* long	CEA* long, sensitivity	CEA* long, population level, per person
Intervention costs	CEA* short	CEA* long	CEA* long, sensitivity	Men	Women
HIT†	117 011	117 011	117 011	801	801
LIT‡	27 927	27 927	27 927	189	189
Difference in intervention costs	89 085	89 085	89 085	612	612
Difference in societal costs avoided	82 253	67 466	32 469	779	502
Incremental costs	6832	21 619	56 616	−167	110
Incremental QALYs§	7.44	5.71	4.82	0.0664	0.0462
Incremental cost per QALY§ (ICER¶)	918	3786	11 746	<0	2391

*Cost-effectiveness analysis.
†High-intensity smoking cessation treatment, the HIT programme.
‡Low-intensity smoking cessation treatment, the LIT programme.
§Quality-adjusted life-years.
¶Incremental cost-effectiveness ratio (ICER) is calculated as incremental costs divided by incremental quality-adjusted life-years (QALYs).